RBC Capital Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $77.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP)

The analyst comments "Updated ASCO data continue to point to competitive efficacy for their Nectin-4 targeted ADC '701, with potential for a differentated safety profile - reaffirming our view the drug could be a viable part of the treatment paradigm across multiple solid tumors (e.g., cervical cancer, potentially later-line mUC and/or head/neck) with $1B out-year combined sales potential. With '701 looking promising and obesity agent '913 likely to gain increasing attention as it progresses into the clinic and data from others CB1 inverse agonists read out, we see upside for CRBP shares."

For an analyst ratings summary and ratings history on Corbus Pharmaceuticals click here. For more ratings news on Corbus Pharmaceuticals click here.

Shares of Corbus Pharmaceuticals closed at $42.80 yesterday.

You May Also Be Interested In

• Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Mizuho
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• New Street Research Upgrades Micron Technology (MU) to Buy